HIV Infections
Conditions
Keywords
HBV vaccine, HIV children, immune recovery, HBV antibody, Intradermal, Intramuscular, antibody response after HBV vaccine, treatment experienced
Brief summary
The purpose of this study is : * To evaluate prevalence of protective hepatitis B antibody comparing intradermal (ID) and intramuscular (IM) route in antiHbsAb negative HIV infected children treated with highly active antiretroviral therapy (HAART) * To revaccinate the HBV vaccine in the children who didn't have protective HBV Ab
Detailed description
Hepatitis B virus (HBV) and HIV share the same route of transmission and can have co-infection. The prevalence of this co-infection was 8.7% in Thai adult\[1, 2\] and 12.1% in African HIV vertically transmitted children\[3\]. Occurrence of HBV has effects to treatment due to having the same medication, lamivudine, tenofovir, emtricitabine or entecavir, to anti HIV medication. HBV can cause chronic liver disease, cirrhosis and hepatocellular carcinoma. In Thailand, the routine HBV vaccination program was started since 1992. Few reports in severe immune compromise HIV children has been shown to lose their expected preventive measles and hepatitis B antibody from history of scheduled vaccination even after the immune recovery by HAART\[4, 5\]. Limited data in of prevalence of protective hepatitis B antibody response after immune recovery in Thai HIV infected children treated with highly active antiretroviral therapy. In addition, HBV revaccination in this group of children should be considered\[6\]. The response of HBV revaccination intramuscularly (IM) at 0, 2 and 6 months in 63 HIV children shown response rates 17.4, 82.5, and 92.1% at 2, 6 and 7 months respectively\[6\]. Protective anti-HBs were shown in the majority of non-responders to IM HBV vaccine health care workers \[21/23 (91.3%)\] by two doses of intradermal route (ID)\[7\]. We hypothesize to see the faster and higher response of antiHBs after first dose of ID compare to IM in anti HBsAb negative HIV infected children. No randomized control trial compare antibody response between IM and ID route in HIV children after immune recovery. The benefit from this trial would be decreased the vaccine cost for resourced limited country.
Interventions
BIOLOGICALIntradermal HBV 1 course
Dosage: 2 microgram (mcg), 0.1 ml per dose Location: left deltoid area x 1 injection Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months
BIOLOGICALIntramuscular HBV I course
Dosage: 2 microgram (mcg), 0.1 ml per dose Location: left deltoid area x 1 injection Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months
Sponsors
ART AIDS Charity Fund
The HIV Netherlands Australia Thailand Research Collaboration
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
1 Years to 18 Years
Healthy volunteers
No
Inclusion criteria
* HIV infected individuals * Age 1-18 years * Current CD4 within 6 months ≥ 15% or ≥ 200 cells/ml in children age ≥ 6 years * Signed written informed consent * Negative HBs Ag, antiHBs, and antiHBc at screening visit
Exclusion criteria
* Active AIDS * Active opportunistic infection * Platelet \< 50,000/ mm3 at screening visit * History of hypersensitivity to HBV vaccine * Using oral steroid or immunosuppressive drugs
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of children with protective antiHBs at 8 weeks after first dose of HBV ID is superior to HBV IM | 8 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of children with positive antiHBs at 4 weeks after second and third dose of HBV | 4 weeks |
| Number of adverse events in HBV ID group and HBV IM group | 7 months |
| Proportion of protective antiHBs in HIV children after protocol defining immune recovery | 7 months |
Countries
Thailand
Outcome results
None listed